Fox Business Varney & Co. Features MedTech Emerger NeuroOne® CEO Dave Rosa

Chief Executive Officer for the emerging MedTech company NeuroOne Medical Technologies Corporation (NMTC) was featured on the Fox Business Network’s news and talk show, Varney & Co. this past Wednesday. The company released an official announcement highlighting the appearance in which they discussed a new brain implant that could have a significant impact on neurosurgery.

Assisting In Revolutionary Neurological Discoveries to Treat Seizure Patients

The PRISM MedDevices Index company focuses on improving surgical care options and outcomes for patients suffering from neurological disorders. Not to be confused with a chip, their device is an electrode that is placed in the brain and is the first electrode implant cleared by the FDA that provides EEG recording capabilities as well as nervous tissue RF ablation, and is known as the Evo® sEEG-RF electrode, and it works in conjunction with NeuroOne’s recently FDA-cleared OneRF™ ablation system.

How the NeuroOne’s OneRF™ Ablation System Works

Typically, 15 of these electrodes are implanted in the brain and connected to a diagnostic recording system. The recording system takes what is similar to an EKG of the brain, to monitor activity and locate problematic areas that can cause seizures in patients. This is done performing only one surgery.

Once the problematic area has been identified by the neurosurgeon, he connects the Evo® sEEG-RF Electrode to a OneRF™ generator that provides heat through the electrode that will destroy the tissue in an attempt to neutralize the epileptic seizures. Once complete, the surgeon can then reconnect the electrode to the diagnostic recording equipment, continue recording brain activity and evaluate the outcome of the surgery.

The device’s first human implant specifically intended to use the OneRF Ablation System will take place this month at the Mayo Clinic.

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.

 

Caution: Federal law restricts this device to sale by or on the order of a physician.

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Read Full Disclaimer

Share This Article

 

About the Author

Fox Business Varney & Co. Features MedTech Emerger NeuroOne® CEO Dave Rosa

Ashlee Vogenthaler

Markets Editor